“…Many studies have shown that polydatin has a wide range of pharmacological activities, such as anti‐fibrosis, anti‐tumor, anti‐atherosclerotic diseases, anti‐hepatitis, protection against multi‐organ ischemia–reperfusion injury and dementia‐related disorders, and so on (Li et al, 2018; Sun & Wang, 2020; Wu et al, 2020; Jin et al, 2020; Chen, Niu, et al, 2020; Liu et al, 2020; Tang, 2021). In the past decade, it has been reported that polydatin can improve dextran sulfate sodium (DSS) or dinitro‐benzene sulfonic acid (DNBS)‐induced colitis by anti‐inflammation, anti‐oxidation and anti‐apoptosis, and its mechanism of action involves the Sonic hedgehog pathway, the nuclear factor kappa B (NF‐κB) pathway, the sirtuin 1/nuclear factor erythroid 2‐related factor 2 (SIRT‐1/Nrf2) pathway, and the mitogen‐activated protein kinase (MAPK) pathway (Chen et al, 2021; Peritore et al, 2021; Lv et al, 2018; Ebrahim & Elsherbini, 2021; Yao et al, 2011; Liu et al, 2018). However, it is rarely reported that polydatin regulates Th17/Treg balance and its molecular mechanism to alleviate colitis.…”